...
supn-img

Supernus Pharmaceuticals Inc, Common Stock

SUPN

NMQ

$35.517

-$0.7

(-1.93%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.00B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
33.8505
Volume info-icon
This is the total number of shares traded during the most recent trading day.
117.44K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.87
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$25.53 L
$39.37 H
$35.517

About Supernus Pharmaceuticals Inc, Common Stock

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameSUPNSectorS&P500
1-Week Return-1.42%-3.39%0.2%
1-Month Return2.75%-1.92%2.72%
3-Month Return14.19%-10.54%7.31%
6-Month Return39.36%-4.47%10.44%
1-Year Return32.72%4.06%27.53%
3-Year Return26.25%0.94%30.88%
5-Year Return57.55%36.67%89.21%
10-Year Return314.42%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue392.75M520.40M579.77M667.24M607.52M[{"date":"2019-12-31","value":58.86,"profit":true},{"date":"2020-12-31","value":77.99,"profit":true},{"date":"2021-12-31","value":86.89,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.05,"profit":true}]
Cost of Revenue16.66M52.46M75.06M87.22M83.78M[{"date":"2019-12-31","value":19.1,"profit":true},{"date":"2020-12-31","value":60.14,"profit":true},{"date":"2021-12-31","value":86.06,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.05,"profit":true}]
Gross Profit376.10M467.94M504.71M580.02M523.74M[{"date":"2019-12-31","value":64.84,"profit":true},{"date":"2020-12-31","value":80.68,"profit":true},{"date":"2021-12-31","value":87.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":90.3,"profit":true}]
Gross Margin95.76%89.92%87.05%86.93%86.21%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":93.9,"profit":true},{"date":"2021-12-31","value":90.91,"profit":true},{"date":"2022-12-31","value":90.78,"profit":true},{"date":"2023-12-31","value":90.03,"profit":true}]
Operating Expenses227.52M292.34M425.21M534.40M529.01M[{"date":"2019-12-31","value":42.58,"profit":true},{"date":"2020-12-31","value":54.7,"profit":true},{"date":"2021-12-31","value":79.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.99,"profit":true}]
Operating Income148.57M173.70M86.03M67.30M(5.27M)[{"date":"2019-12-31","value":85.53,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":49.53,"profit":true},{"date":"2022-12-31","value":38.75,"profit":true},{"date":"2023-12-31","value":-3.03,"profit":false}]
Total Non-Operating Income/Expense(2.17M)(10.10M)(25.71M)29.24M14.90M[{"date":"2019-12-31","value":-7.42,"profit":false},{"date":"2020-12-31","value":-34.54,"profit":false},{"date":"2021-12-31","value":-87.93,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":50.95,"profit":true}]
Pre-Tax Income147.49M168.65M73.17M60.74M2.77M[{"date":"2019-12-31","value":87.45,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":43.39,"profit":true},{"date":"2022-12-31","value":36.02,"profit":true},{"date":"2023-12-31","value":1.64,"profit":true}]
Income Taxes34.43M41.70M19.75M32.00K1.45M[{"date":"2019-12-31","value":82.57,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":47.37,"profit":true},{"date":"2022-12-31","value":0.08,"profit":true},{"date":"2023-12-31","value":3.48,"profit":true}]
Income After Taxes113.06M126.95M53.42M60.71M1.32M[{"date":"2019-12-31","value":89.06,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":47.82,"profit":true},{"date":"2023-12-31","value":1.04,"profit":true}]
Income From Continuous Operations113.06M126.95M53.42M60.71M25.62M[{"date":"2019-12-31","value":89.06,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":47.82,"profit":true},{"date":"2023-12-31","value":20.18,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income113.06M126.95M53.42M60.71M1.32M[{"date":"2019-12-31","value":89.06,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":47.82,"profit":true},{"date":"2023-12-31","value":1.04,"profit":true}]
EPS (Diluted)2.112.360.981.031.40[{"date":"2019-12-31","value":89.41,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":41.53,"profit":true},{"date":"2022-12-31","value":43.64,"profit":true},{"date":"2023-12-31","value":59.32,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SUPN
Cash Ratio 1.38
Current Ratio 2.20
Quick Ratio 1.98

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SUPN
ROA (LTM) 2.89%
ROE (LTM) 6.22%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SUPN
Debt Ratio Lower is generally better. Negative is bad. 0.25
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.75

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SUPN
Trailing PE 33.85
Forward PE 20.16
P/S (TTM) 3.07
P/B 2.00
Price/FCF 38
EV/R 2.53
EV/Ebitda 10.60
PEG 1.47

FAQs

What is Supernus Pharmaceuticals Inc share price today?

Supernus Pharmaceuticals Inc (SUPN) share price today is $35.517

Can Indians buy Supernus Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Supernus Pharmaceuticals Inc (SUPN) on Vested. To buy Supernus Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SUPN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Supernus Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Supernus Pharmaceuticals Inc (SUPN) via the Vested app. You can start investing in Supernus Pharmaceuticals Inc (SUPN) with a minimum investment of $1.

How to invest in Supernus Pharmaceuticals Inc shares from India?

You can invest in shares of Supernus Pharmaceuticals Inc (SUPN) via Vested in three simple steps:

  • Click on Sign Up or Invest in SUPN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Supernus Pharmaceuticals Inc shares
What is Supernus Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Supernus Pharmaceuticals Inc (SUPN) is $39.37. The 52-week low price of Supernus Pharmaceuticals Inc (SUPN) is $25.53.

What is Supernus Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Supernus Pharmaceuticals Inc (SUPN) is 33.8505

What is Supernus Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Supernus Pharmaceuticals Inc (SUPN) is 2.00

What is Supernus Pharmaceuticals Inc dividend yield?

The dividend yield of Supernus Pharmaceuticals Inc (SUPN) is 0.00%

What is the Market Cap of Supernus Pharmaceuticals Inc?

The market capitalization of Supernus Pharmaceuticals Inc (SUPN) is $2.00B

What is Supernus Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Supernus Pharmaceuticals Inc is SUPN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top